| Project/Area Number |
17K17735
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
Tumor therapeutics
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | glioma / EUrd / Glioblastoma / temozolomide / 膠芽腫 / TMZ耐性 / glioblastoma / CED / Glioma stem cell |
|---|
| Outline of Final Research Achievements |
This study examined the efficacy of Convection enhanced delivery theraphy (CED) with EUrd, a newly identified therapeutic agent, for human-derived tumor cell lines and animal xenograft models resistant to temozolomide. Two temozolomide-resistant brain tumor cell lines were established. Each cell line proved to be sufficiently capable of cell experimentation, and the NGT41 cell line could almost certainly generate brain tumor models in immunocompromised mice. In the future, we plan to proceed with CED treatment experiments using EUrd.
|
| Academic Significance and Societal Importance of the Research Achievements |
膠芽腫は集学的な治療が行われる。治療初期は腫瘍の縮小などの効果が見られるが、徐々に治療耐性化することが問題である。本研究ではテモゾロミド耐性細胞への新規治療の研究である。ここまでの期間で、新規治療の研究に不可欠なヒト由来の脳腫瘍細胞株と免疫不全マウスへの移植モデルを確立した。またNGT41という細胞株でのモデルは、実際の患者さんと同様の薬剤を投与し、同様の治療経過を取ることも実証した。このようなマウスモデルは悪性神経膠腫などの悪性脳腫瘍への新規治療薬開発の為に大きな意義があると考えられる。
|
